Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1263-1277
Open Access | Times Cited: 148

Showing 1-25 of 148 citing articles:

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Aruna D. Pradhan, Robert J. Glynn, Jean‐Charles Fruchart, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 21, pp. 1923-1934
Open Access | Times Cited: 456
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 252
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 203
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 152
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei‐Chuan Lee, Pei-Shan Wu, Han‐Chieh Lin
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 1, pp. 77-98
Open Access | Times Cited: 113
PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
Simona Todisco, Anna Santarsiero, Paolo Convertini, et al.
Biology (2022) Vol. 11, Iss. 5, pp. 792-792
Open Access | Times Cited: 76
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
Paloma Sangro, Manuel de la Torre‐Aláez, Bruno Sangro, et al.
Journal of Physiology and Biochemistry (2023) Vol. 79, Iss. 4, pp. 869-879
Open Access | Times Cited: 66
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Li Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 57
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15473-15473
Open Access | Times Cited: 49
Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Chunye Zhang, Shuai Liu, Ming Yang
World Journal of Hepatology (2023) Vol. 15, Iss. 2, pp. 180-200
Open Access | Times Cited: 44
Treating NASH by targeting peroxisome proliferator-activated receptors
Bart Staels, Laura Butruille, Sven Francque
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1302-1316
Open Access | Times Cited: 44
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 35
A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1
Suchira Gallage, Adnan Ali, Jose Efren Barragan Avila, et al.
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1371-1393.e7
Open Access | Times Cited: 30
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5640-5640
Open Access | Times Cited: 21
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 140-140
Open Access | Times Cited: 2
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1778-1778
Open Access | Times Cited: 2
Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome
Takashi Kobayashi, Michihiro Iwaki, Atsushi Nakajima, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11689-11689
Open Access | Times Cited: 59
Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort
Kento Imajo, Hidenori Toyoda, Satoshi Yasuda, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 11, pp. 2533-2541.e7
Open Access | Times Cited: 58
Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality
Mayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 55, Iss. 3, pp. 292-301
Open Access | Times Cited: 56
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4305-4305
Open Access | Times Cited: 54
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
Nobuharu Tamaki, Masayuki Kurosaki, Daniel Q. Huang, et al.
Hepatology Research (2022) Vol. 52, Iss. 6, pp. 497-507
Open Access | Times Cited: 47
Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
S Kamata, Akihiro Honda, Isao Ishii
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1264-1264
Open Access | Times Cited: 35
Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
Guocheng Rao, Xi Peng, Xinqiong Li, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 24
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Michael Cooreman, Luisa Vonghia, Sven Francque
Diabetes Research and Clinical Practice (2024) Vol. 212, pp. 111688-111688
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top